Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation
Clinical Transplantation · 2026-03 · 40 (3)
DOI: 10.1111/ctr.70495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 05.03.2026. Verfasst von David I Harriman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Alemtuzumab, Kidney Transplantation, Graft Survival, Graft Rejection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The anti‐CD52 monoclonal antibody alemtuzumab is used as an induction agent in kidney transplantation (KT) but remains understudied in septuagenarian recipients. The study purpose was to analyze the safety and efficacy of single‐dose alemtuzumab induction in septuagenarian deceased donor (DD) KT recipients.
Methods
Single center retrospective nonrandomized cohort review of septuagenarian DDKT recipients stratified by induction immunosuppression (single dose alemtuzumab versus multi‐dose rabbit anti‐thymocyte globulin [ATG]). Standardized management algorithms were used, and all patients received maintenance immunosuppression with tacrolimus/mycophenolate/steroids.
Results
From November 2003 to December 2024, 359 DDKTs were performed in septuagenarian recipients with either alemtuzumab ( n = 270) or ATG induction ( n = 89). Donor and recipient characteristics were largely comparable between the two groups. Five‐year patient (70.3% alemtuzumab versus 82.9% ATG, p = 0.054), graft (60.2% alemtuzumab versus 74.7% ATG, p = 0.04) and death‐censored graft survival (80.0% alemtuzumab versus 89.1% ATG, p = 0.11) rates favored the ATG cohort.
Conclusion
ATG induction was associated with improved survival outcomes in our cohort and may be the preferred induction agent in septuagenarians undergoing DDKT versus alemtuzumab. Given the findings of our study, caution is warranted with the use of alemtuzumab in elderly KT patients receiving triple maintenance immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Surgery, Section of Transplantation, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Internal Medicine, Section of Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
ORCID-Profile: David I Harriman, Alex Ng, Alan C Farney, Giuseppe Orlando, Colleen Jay, Robert J Stratta
Zitieren
APA
Harriman, D. I., Ng, A., Farney, A. C., Orlando, G., Jay, C., Reeves-Daniel, A., & Stratta, R. J. (2026). Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation. Clinical Transplantation, 40(3). https://doi.org/10.1111/ctr.70495
Vancouver
Harriman DI, Ng A, Farney AC, Orlando G, Jay C, Reeves-Daniel A, et al. Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation. Clinical Transplantation. 2026;40(3). doi:10.1111/ctr.70495
BibTeX
@article{Harriman2026,
author = {Harriman, David I and Ng, Alex and Farney, Alan C and Orlando, Giuseppe and Jay, Colleen and Reeves-Daniel, Amber and Stratta, Robert J},
title = {Alemtuzumab Induction in Septuagenarians Undergoing Deceased Donor Kidney Transplantation},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {3},
doi = {10.1111/ctr.70495}
}
EUVIMED